{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:19:12Z","timestamp":1776262752406,"version":"3.50.1"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2004,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            ME1036, formerly CP5609, is a novel parenteral carbapenem with a 7-acylated imidazo[5,1-\n            <jats:italic>b<\/jats:italic>\n            ]thiazole-2-yl group directly attached to the carbapenem moiety of the C-2 position. The present study evaluated the in vitro activities of ME1036 against clinical isolates of gram-positive and gram-negative bacteria. ME1036 displayed broad activity against aerobic gram-positive and gram-negative bacteria. Unlike other marketed \u03b2-lactam antibiotics, ME1036 maintained excellent activity against multiple-drug-resistant gram-positive bacteria, such as methicillin-resistant staphylococci and penicillin-resistant\n            <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n            (PRSP). The MICs of this compound at which 90% of isolates were inhibited were 2 \u03bcg\/ml for methicillin-resistant\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            (MRSA), 2 \u03bcg\/ml for methicillin-resistant coagulase-negative staphylococci, and 0.031 \u03bcg\/ml for PRSP. In time-kill studies with six strains of MRSA, ME1036 at four times the MIC caused a time-dependent decrease in the numbers of viable MRSA cells. The activity of ME1036 against MRSA is related to its high affinity for penicillin-binding protein 2a, for which the 50% inhibitory concentration of ME1036 was approximately 300-fold lower than that of imipenem. In conclusion, ME1036 demonstrated a broad antibacterial spectrum and high levels of activity in vitro against staphylococci, including \u03b2-lactam-resistant strains.\n          <\/jats:p>","DOI":"10.1128\/aac.48.8.2831-2837.2004","type":"journal-article","created":{"date-parts":[[2004,7,23]],"date-time":"2004-07-23T18:45:20Z","timestamp":1090608320000},"page":"2831-2837","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":37,"title":["In Vitro Activities of ME1036 (CP5609), a Novel Parenteral Carbapenem, against Methicillin-Resistant Staphylococci"],"prefix":"10.1128","volume":"48","author":[{"given":"Mizuyo","family":"Kurazono","sequence":"first","affiliation":[{"name":"Pharmaceutical Research Center, Meiji Seika Kaisha Ltd., 760 Morooka-cho, Kohoku-ku, Yokohama 222-8567, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ida","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Center, Meiji Seika Kaisha Ltd., 760 Morooka-cho, Kohoku-ku, Yokohama 222-8567, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Yamada","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Center, Meiji Seika Kaisha Ltd., 760 Morooka-cho, Kohoku-ku, Yokohama 222-8567, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Hirai","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Center, Meiji Seika Kaisha Ltd., 760 Morooka-cho, Kohoku-ku, Yokohama 222-8567, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Center, Meiji Seika Kaisha Ltd., 760 Morooka-cho, Kohoku-ku, Yokohama 222-8567, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiki","family":"Shitara","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Center, Meiji Seika Kaisha Ltd., 760 Morooka-cho, Kohoku-ku, Yokohama 222-8567, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Yonezawa","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Center, Meiji Seika Kaisha Ltd., 760 Morooka-cho, Kohoku-ku, Yokohama 222-8567, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"902","volume":"51","year":"2002","unstructured":"Centers for Disease Control and Prevention. 2002. Vancomycin-resistant Staphylococcus aureus\u2014Pennsylvania, 2002. Morb. Mortal. Wkly. Rep.51:902.","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_3_2","first-page":"565","volume":"51","year":"2002","unstructured":"Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin\u2014United States, 2002. Morb. Mortal. Wkly. Rep.51:565-567.","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.5.1422-1430.2001"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.2.462"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.1999.5.163"},{"key":"e_1_3_2_7_2","first-page":"S114","volume":"15","year":"2001","unstructured":"Diekema, D. J., M. A. Pfaller, F. J. Schmitz, J. Smayevsky, J. Bell, R. N. Jones, M. Beach, and SENTRY Participants Group. 2001. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis.15:S114-S132.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.10.3727-3732.2001"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-5231(05)70143-X"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.158.2.513-516.1984"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.7164\/antibiotics.47.606","volume":"47","year":"1994","unstructured":"Hayashi, I., M. Inoue, and H. Hashimoto. 1994. Questionnaires regarding MRSA in Japan. Jpn. J. Antibiot.47:606-617. (In Japanese.)","journal-title":"Jpn. J. Antibiot."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.825-836.2001"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.1992.tb02043.x"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s101560200024","volume":"8","year":"2002","unstructured":"Ida, T., M. Tsushima, T. Ishii, K. Atsumi, and A. Tamura. 2002. CP6679, a new injectable cephalosporin with broad spectrum and potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. J. Infect. Chemother.8:138-144.","journal-title":"J. Infect. Chemother."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.815-824.2001"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/BF02347727","volume":"1","year":"1995","unstructured":"Konno, M. 1995. Nosocomial infections caused by methicillin-resistant Staphylococcus aureus in Japan. J. Infect. Chemother.1:30-39.","journal-title":"J. Infect. Chemother."},{"key":"e_1_3_2_17_2","first-page":"5.3.1","volume":"1","year":"1992","unstructured":"Leitch, C., and S. Boonlayangoor. 1992. \u03b2-Lactamase tests, p. 5.3.1-5.3.8. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook,vol. 1. American Society for Microbiology, Washington, D.C.","journal-title":"Clinical microbiology procedures handbook"},{"key":"e_1_3_2_18_2","unstructured":"National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1067\/mic.2001.119952"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.6.1693-1699.2001"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.8.2471-2480.2003"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.28.3.397"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.8.2831-2837.2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.8.2831-2837.2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:26:38Z","timestamp":1645467998000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.48.8.2831-2837.2004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["10.1128\/AAC.48.8.2831-2837.2004"],"URL":"https:\/\/doi.org\/10.1128\/aac.48.8.2831-2837.2004","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8]]},"assertion":[{"value":"2003-11-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-04-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}